CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice

Experimental Hematology

Volumn 34, Issue 6, 2006, Pages 721-727

  Carlo Stella, Carmelo ^a,b   Guidetti, Anna ^a   Di Nicola, Massimo ^a   Longoni, Paolo ^a   Cleris, Loredana ^a   Lavazza, Cristiana ^a,b   Milanesi, Marco ^a   Milani, Raffaella ^a   Carrabba, Matteo ^a   Farina, Lucia ^a   Formelli, Franca ^a   Gianni, Alessandro M ^a,b   Corradini, Paolo ^a,b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD52 ANTIGEN; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISOLONE; SYNDECAN 1; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PROTEOGLYCAN; RNA; SDC1 PROTEIN, HUMAN; SDC1 PROTEIN, MOUSE; SYNDECAN; TUMOR ANTIGEN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN DETECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL HETEROGENEITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE; XENOGRAFT; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOLOGY;

ANIMALIA;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; MULTIPLE MYELOMA; PROTEOGLYCANS; RNA, NEOPLASM; SYNDECAN-1; SYNDECANS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33745949229     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2006.03.005     Document Type: Article

References (29)

1. Bataille R., and Harousseau J.L. Multiple myeloma. N Engl J Med 336 (1997) 1657-1664
2. Kyle R.A., and Rajkumar S.V. Multiple myeloma. N Engl J Med 351 (2004) 1860-1873
3. Greipp P.R., San Miguel J., Durie B.G., et al. International staging system for multiple myeloma. J Clin Oncol 23 (2005) 3412-3420
4. Barlogie B., Shaughnessy J., Tricot G., et al. Treatment of multiple myeloma. Blood 103 (2004) 20-32
5. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 (2003) 2609-2617
6. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 (2005) 2487-2498
7. Coiffier B. Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma. Blood Rev 17 (2003) 25-31
8. Burton J.D., Ely S., Reddy P.K., et al. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res 10 (2004) 6606-6611
9. Liebisch P., Eppinger S., Schopflin C., et al. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. Haematologica 90 (2005) 489-493
10. + multiple myeloma cells. Blood 104 (2004) 3688-3696
11. Hale G., Xia M.Q., Tighe H.P., Dyer M.J., and Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 35 (1990) 118-127
12. Treumann A., Lifely M.R., Schneider P., and Ferguson M.A. Primary structure of CD52. J Biol Chem 270 (1995) 6088-6099
13. Gilleece M.H., and Dexter T.M. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 82 (1993) 807-812
14. Hale G., Bright S., Chumbley G., et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 62 (1983) 873-882
15. Keating M.J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99 (2002) 3554-3561
16. Lozanski G., Heerema N.A., Flinn I.W., et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103 (2004) 3278-3281
17. Osterborg A., Dyer M.J., Bunjes D., et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15 (1997) 1567-1574
18. Rai K.R., Freter C.E., Mercier R.J., et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20 (2002) 3891-3897
19. Kumar S., Kimlinger T.K., Lust J.A., Donovan K., and Witzig T.E. Expression of CD52 on plasma cells in plasma cell proliferative disorders. Blood 102 (2003) 1075-1077
20. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25 (2001) 402-408
21. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 58 (1988) 109-113
22. Dodero A., Carrabba M., Milani R., et al. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. Exp Hematol 33 (2005) 920-927
23. Schneider U., van Lessen A., Huhn D., and Serke S. Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen. Br J Haematol 97 (1997) 56-64
24. +) 5T multiple myeloma cells. Exp Hematol 29 (2001) 77-84
25. Westermann J., Maschmeyer G., van Lessen A., Dorken B., and Pezzutto A. CD52 is not a promising immunotherapy target for most patients with multiple myeloma. Int J Hematol 82 (2005) 248-250
26. Bertolini F., Fusetti L., Mancuso P., et al. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood 96 (2000) 282-287
27. Wang E.S., Teruya-Feldstein J., Wu Y., et al. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 104 (2004) 2893-2902
28. Lundin J., Kimby E., Bjorkholm M., et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100 (2002) 768-773
29. Keating M.J., Cazin B., Coutre S., et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 20 (2002) 205-213